Protein Transduction Domain-Mediated Delivery of Recombinant Proteins and In Vitro Transcribed mRNAs for Protein Replacement Therapy of Human Severe Genetic Mitochondrial Disorders: The Case of Sco2 Deficiency
Authors:
- Androulla N. MiliotouAMAndroulla N. Miliotou
- Parthena F. FoltopoulouPFParthena F. Foltopoulou
- Alexandra Ingendoh-TsakmakidisAIAlexandra Ingendoh-Tsakmakidis
- Asterios S. TsiftsoglouATAsterios S. Tsiftsoglou
- Ioannis S. VizirianakisIoannis S. Vizirianakis
- Ioannis S. PappasIoannis S. Pappas
- Lefkothea C. PapadopoulouLPLefkothea C. Papadopoulou
Open Access
- 14 January 2023
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (1) , 286
Abstract
Mitochondrial disorders represent a heterogeneous group of genetic disorders with variations in severity and clinical outcomes, mostly characterized by respiratory chain dysfunction and abnormal mitochondrial function. More specifically, mutations in the human SCO2 gene, encoding the mitochondrial inner membrane Sco2 cytochrome c oxidase (COX) assembly protein, have been implicated in the mitochondrial disorder fatal infantile cardioencephalomyopathy with COX deficiency. Since an effective treatment is still missing, a protein replacement therapy (PRT) was explored using protein transduction domain (PTD) technology. Therefore, the human recombinant full-length mitochondrial protein Sco2, fused to TAT peptide (a common PTD), was produced (fusion Sco2 protein) and successfully transduced into fibroblasts derived from a SCO2/COX-deficient patient. This PRT contributed to effective COX assembly and partial recovery of COX activity. In mice, radiolabeled fusion Sco2 protein was biodistributed in the peripheral tissues of mice and successfully delivered into their mitochondria. Complementary to that, an mRNA-based therapeutic approach has been more recently considered as an innovative treatment option. In particular, a patented, novel PTD-mediated IVT-mRNA delivery platform was developed and applied in recent research efforts. PTD-IVT-mRNA of full-length SCO2 was successfully transduced into the fibroblasts derived from a SCO2/COX-deficient patient, translated in host ribosomes into a nascent chain of human Sco2, imported into mitochondria, and processed to the mature protein. Consequently, the recovery of reduced COX activity was achieved, thus suggesting the potential of this mRNA-based technology for clinical translation as a PRT for metabolic/genetic disorders. In this review, such research efforts will be comprehensibly presented and discussed to elaborate their potential in clinical application and therapeutic usefulness.Keywords
This publication has 307 references indexed in Scilit:
- NDUFA4 Mutations Underlie Dysfunction of a Cytochrome c Oxidase Subunit Linked to Human Neurological DiseaseCell Reports, 2013
- Mutations in SCO2 Are Associated with Autosomal-Dominant High-Grade MyopiaThe American Journal of Human Genetics, 2013
- Mutations in COX7B Cause Microphthalmia with Linear Skin Lesions, an Unconventional Mitochondrial DiseaseThe American Journal of Human Genetics, 2012
- Mutations in C12orf62, a Factor that Couples COX I Synthesis with Cytochrome c Oxidase Assembly, Cause Fatal Neonatal Lactic AcidosisThe American Journal of Human Genetics, 2012
- A Mutation in C2orf64 Causes Impaired Cytochrome c Oxidase Assembly and Mitochondrial CardiomyopathyThe American Journal of Human Genetics, 2011
- A Short Pulse of IL-4 Delivered by DCs Electroporated With Modified mRNA Can Both Prevent and Treat Autoimmune Diabetes in NOD MiceMolecular Therapy, 2010
- Human Iron−Sulfur Cluster Assembly, Cellular Iron Homeostasis, and DiseaseBiochemistry, 2010
- Severe Infantile Encephalomyopathy Caused by a Mutation in COX6B1, a Nucleus-Encoded Subunit of Cytochrome C OxidaseThe American Journal of Human Genetics, 2008
- Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migrationNature Medicine, 1998
- On the origin of mitosing cellsJournal of Theoretical Biology, 1967